JP2016530299A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530299A5
JP2016530299A5 JP2016540401A JP2016540401A JP2016530299A5 JP 2016530299 A5 JP2016530299 A5 JP 2016530299A5 JP 2016540401 A JP2016540401 A JP 2016540401A JP 2016540401 A JP2016540401 A JP 2016540401A JP 2016530299 A5 JP2016530299 A5 JP 2016530299A5
Authority
JP
Japan
Prior art keywords
diazaspiro
decane
amino
pyrimidin
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530299A (ja
JP6470290B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054202 external-priority patent/WO2015035113A1/en
Publication of JP2016530299A publication Critical patent/JP2016530299A/ja
Publication of JP2016530299A5 publication Critical patent/JP2016530299A5/ja
Application granted granted Critical
Publication of JP6470290B2 publication Critical patent/JP6470290B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540401A 2013-09-06 2014-09-05 トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物 Expired - Fee Related JP6470290B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361874545P 2013-09-06 2013-09-06
US61/874,545 2013-09-06
US201361899943P 2013-11-05 2013-11-05
US61/899,943 2013-11-05
US201462004385P 2014-05-29 2014-05-29
US62/004,385 2014-05-29
PCT/US2014/054202 WO2015035113A1 (en) 2013-09-06 2014-09-05 Spirocyclic compounds as tryptophan hydroxylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016530299A JP2016530299A (ja) 2016-09-29
JP2016530299A5 true JP2016530299A5 (enExample) 2017-10-12
JP6470290B2 JP6470290B2 (ja) 2019-02-13

Family

ID=51743540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540401A Expired - Fee Related JP6470290B2 (ja) 2013-09-06 2014-09-05 トリプトファンヒドロキシラーゼ阻害薬としてのスピロ環式化合物

Country Status (30)

Country Link
US (8) US9199994B2 (enExample)
EP (1) EP3041842B8 (enExample)
JP (1) JP6470290B2 (enExample)
KR (1) KR102336075B1 (enExample)
CN (1) CN105764902B (enExample)
AR (1) AR097571A1 (enExample)
AU (1) AU2014315109B2 (enExample)
CA (1) CA2922933C (enExample)
CL (1) CL2016000509A1 (enExample)
CY (1) CY1122652T1 (enExample)
DK (1) DK3041842T3 (enExample)
EA (1) EA032304B1 (enExample)
EC (1) ECSP16014324A (enExample)
ES (1) ES2780828T3 (enExample)
HR (1) HRP20200098T1 (enExample)
HU (1) HUE047574T2 (enExample)
IL (1) IL244315B (enExample)
LT (1) LT3041842T (enExample)
MX (1) MX371191B (enExample)
MY (1) MY186265A (enExample)
PE (1) PE20160648A1 (enExample)
PH (1) PH12016500416A1 (enExample)
PL (1) PL3041842T3 (enExample)
PT (1) PT3041842T (enExample)
RS (1) RS59871B1 (enExample)
SG (2) SG10201802118QA (enExample)
SI (1) SI3041842T1 (enExample)
TW (1) TWI652267B (enExample)
UA (1) UA119247C2 (enExample)
WO (1) WO2015035113A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN107176940B (zh) * 2016-03-09 2019-05-28 江苏正大丰海制药有限公司 一种替卡法林的制备方法
TW201818964A (zh) * 2016-09-30 2018-06-01 瑞士商諾伊曼特醫療公司 使用色胺酸羥化酶抑制劑之方法
AR110150A1 (es) 2016-11-09 2019-02-27 Roivant Sciences Gmbh Procesos para la preparación de inhibidores de tph1
US10472313B1 (en) 2018-02-18 2019-11-12 Graphene 3D Lab Inc. Process for synthesizing trifluoroketones
KR20210102887A (ko) 2018-11-14 2021-08-20 알타반트 사이언시스 게엠베하 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제
AU2019382168A1 (en) 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
WO2020128614A1 (en) 2018-12-17 2020-06-25 Altavant Sciences Gmbh Method for treating interstital lung disease
US20200188398A1 (en) 2018-12-17 2020-06-18 Altavant Sciences Gmbh Method for treating sarcoidosis-associated pulmonary hypertension
CN113557022A (zh) * 2019-01-30 2021-10-26 阿尔塔万特科学公司 用罗达司他乙酯治疗肺动脉高压的给药方案和方法
CN113784717A (zh) * 2019-03-15 2021-12-10 阿尔塔万特科学公司 一种治疗肺动脉高压和相关性肺动脉高压的方法以及每日给药
JP2023529764A (ja) * 2019-12-02 2023-07-12 アルタバント・サイエンシズ・ゲーエムベーハー 下気道障害の処置
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
JP2023512025A (ja) * 2020-01-31 2023-03-23 アルタバント・サイエンシズ・ゲーエムベーハー 肺動脈性肺高血圧症をロダトリスタットで処置するための投与量および方法
WO2023062595A1 (en) * 2021-10-14 2023-04-20 Altavant Sciences Gmbh Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl
WO2023079486A1 (en) 2021-11-03 2023-05-11 Altavant Sciences Gmbh Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan
JP2026506896A (ja) * 2023-02-09 2026-02-27 ジェロン・コーポレーション テロメラーゼ阻害剤化合物
EP4739314A1 (en) 2023-07-05 2026-05-13 Institut National de la Santé et de la Recherche Médicale Use of tryptophan hydroxylase 1 (tph1) inhibitors for the treatment of atherosclerosis

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) 1989-05-16 1992-08-10 지구르트 퓌터 약제제
TR199900429T2 (xx) 1996-08-28 1999-05-21 The Procter & Gamble Company Spirosiklik metaloproteaz inhibit�rleri.
WO2001066531A1 (de) 2000-03-07 2001-09-13 Aventis Pharma Deutschland Gmbh Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase
BR0214967A (pt) 2001-12-14 2005-05-10 Novo Nordisk As Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
JP2006527212A (ja) 2003-06-12 2006-11-30 ノボ ノルディスク アクティーゼルスカブ ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート
CA2526204A1 (en) 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102005002130A1 (de) 2005-01-17 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
WO2007089335A2 (en) 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
US8252803B2 (en) * 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
EA016781B1 (ru) 2007-05-16 2012-07-30 Эли Лилли Энд Компани Триазолиламинопиримидиновые соединения
CN101815534A (zh) 2007-07-11 2010-08-25 莱西肯医药有限公司 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物
US20090029993A1 (en) 2007-07-26 2009-01-29 Qingyun Liu Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein
US20100255001A1 (en) 2007-09-24 2010-10-07 Universität Zürich Prorektorat Mnw Blockers of serotonin and its receptors for the treatment of hepatitis
NZ588737A (en) 2008-03-31 2012-05-25 Univ Columbia Methods of diagnosing, preventing and treating bone mass diseases
CN101591332B (zh) 2008-05-30 2014-04-16 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
CN104045626B (zh) 2008-05-30 2017-01-11 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
TW201022267A (en) 2008-10-23 2010-06-16 Gruenenthal Gmbh Substituierte pyrimidin-und triazin-derivate
WO2010056992A1 (en) 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
WO2010065333A1 (en) 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
WO2010109442A1 (en) 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Process for the preparation of desloratadine
TW201103540A (en) 2009-06-16 2011-02-01 Ono Pharmaceutical Co Compound having spiro-linked cyclic group and uses thereof
US8796297B2 (en) * 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
US8815883B2 (en) 2009-11-02 2014-08-26 The Trustees Of Columbia Unviersity In The City Of New York Compounds and methods for inhibiting serotonin synthesis
CA2779681A1 (en) 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
CN102711757A (zh) 2009-11-23 2012-10-03 莱西肯医药有限公司 用于治疗肠易激综合征的方法和分析法
CN102753168A (zh) 2010-02-10 2012-10-24 莱西肯医药有限公司 用于治疗转移性骨病的色氨酸羟化酶抑制剂
AU2011218167B2 (en) * 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
BR112013000946B1 (pt) 2010-07-14 2020-09-08 Novartis Ag Compostos heterocíclicos agonistas de receptor de ip, seus usos, composição e combinação farmacêuticas
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
TW201245183A (en) 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013059146A1 (en) 2011-10-17 2013-04-25 Lexicon Pharmaceuticals, Inc. Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
WO2013074889A1 (en) 2011-11-17 2013-05-23 The Trustees Of Columbia University In The City Of New York Methods of treating and preventing leukemia and other cancers of the blood and bone
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
WO2014082034A1 (en) 2012-11-26 2014-05-30 Lexicon Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome
WO2014124523A1 (en) 2013-02-15 2014-08-21 Mcmaster University A method of treating obesity
WO2014195847A2 (en) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Novel use of stable isotope labeled l-tryptophan
UA119247C2 (uk) * 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
AR098436A1 (es) 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
WO2015075025A1 (en) 2013-11-19 2015-05-28 Actelion Pharmaceuticals Ltd Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
EP3061761A1 (en) 2015-02-24 2016-08-31 Max-Delbrück-Centrum für Molekulare Medizin Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
EP3292127A1 (en) 2015-05-04 2018-03-14 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds

Similar Documents

Publication Publication Date Title
HRP20200098T1 (hr) Spirociklični spojevi kao inhibitori triptofan hidroksilaze
US8921357B2 (en) Pyridazinone derivatives
CA2710092C (en) Pyridazinone derivatives
RU2014139601A (ru) Ингибиторы серин/треониновых киназ
CA2747863C (en) Pyridazinone derivatives
US9365562B2 (en) 1,3 substituted azetidine PDE10 inhibitors
AU2016314898B2 (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
JP2019523233A5 (enExample)
JP2014531465A5 (enExample)
KR20100045471A (ko) 피리돈 gpr119 g 단백질-커플링된 수용체 효능제
JP2010508338A5 (enExample)
JP2008513514A5 (enExample)
RU2009120882A (ru) Соединения и композиции, как ингибиторы протеинкиназы
CN102295637A (zh) 5-脂氧合酶活化蛋白(flap)抑制剂
RU2017126199A (ru) Биарильное производное в качестве агониста gpr120
CN1409708A (zh) 酪氨酸激酶抑制剂
US20120041024A1 (en) Quinolyl amines as kinase inhibitors
RU2011107437A (ru) Ингибиторы кинуренин-3-моноксигеназы
EA032609B1 (ru) Соединения аминопиримидинила в качестве ингибиторов jak
KR20080066989A (ko) 5-리폭시게나제-활성화 단백질(flap) 억제제
JP2021505598A (ja) 心不全およびそれに関連する障害の治療または予防に有用なβ−3アドレナリン受容体のモジュレーター
CN1468230A (zh) 化合物
WO2010138585A1 (en) Pyrimidinones as pde10 inhibitors